Prognostic analysis of esophageal cancer patients after neoadjuvant therapy
In conclusion, this study found that immunotherapy did not play a decisive role in neoadjuvant EC therapy. Instead, 1-2 cycles of chemotherapy or chemoradiotherapy were associated with a more favorable prognosis for these patients.
Authors
- Hongxia Cui (ORCID: https://orcid.org/0000-0002-0137-2450)
- Yang Li (ORCID: https://orcid.org/0000-0003-4399-1505)
- Jing Dong (ORCID: https://orcid.org/0000-0001-8077-9859)
- Bingxiang Wang (ORCID: https://orcid.org/0000-0002-7435-3082)
- Cheng Li (ORCID: https://orcid.org/0000-0002-9479-1768)
- Suzhen Wang (ORCID: https://orcid.org/0000-0003-2076-529X)
- Min Gao
Institutions
- North China University of Science and Technology (CN)
- Shandong Tumor Hospital (CN)
- Jining First People's Hospital (CN)
- Shandong First Medical University (CN)
- Tangshan Gongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1553086
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- National Natural Science Foundation of China
- Department of Health of Shandong Province
- Wu Jieping Medical Foundation